TransGenic Group

TransGenic Group Payables Turnover

The Payables Turnover Ratio of TransGenic Group (2342.T) as of Nov 11, 2026 is 25.84. In the previous year, Payables Turnover Ratio was 26.21 — a change of -1.42% (lower).

Payables Turnover

25.84

YoY

-1.42%

Last updated:

Payables Turnover Ratio of TransGenic Group is 2026 25.84 . Payables Turnover Ratio of TransGenic Group was 2025 26.21 . It decreases by -1.42% lower compared to the previous year.

The TransGenic Group Payables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payables Turnover
Date
Payables Turnover
Jan 1, 2019
135.28 JPY
Jan 1, 2020
30.35 JPY
Jan 1, 2021
24.31 JPY
Jan 1, 2022
34.14 JPY
Jan 1, 2023
23.08 JPY
Jan 1, 2024
39.23 JPY
Jan 1, 2025
26.21 JPY
Jan 1, 2026
25.84 JPY
The TransGenic Group Payables Turnover history
YEARPayables TurnoverYoY
25.84-1.42%
26.21-33.19%
39.23+69.97%
23.08-32.39%
34.14+40.44%
24.31-19.89%
30.35-77.57%
135.28+118.64%
61.88-83.23%
368.94+461.21%
65.74+955.37%
6.23-5.80%
6.61—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TransGenic Group Stock analysis

What does TransGenic Group do? TransGenic Group Inc. generates revenue through three business segments. The Contract Research Organization (CRO) segment provides contract clinical tests for pharmaceuticals and foods, including pharmacodynamic and safety pharmacology tests, as well as non-clinical safety tests for pesticides and food. It also offers contract production of genetically modified mice and antibodies, sales of model mice, and development of new biomarkers. The Diagnostic Analysis segment delivers pathological diagnosis services, gene analysis contract services, and drug discovery support for individualized medicine. The TGBS segment provides business succession and revitalization advice and support services, alongside an electronic commerce (EC) business for retail and wholesale of electrical products. The CRO segment serves pharmaceutical and food companies requiring clinical and non-clinical testing services. The Diagnostic Analysis segment targets healthcare providers and researchers needing diagnostic and drug discovery support. The TGBS segment caters to businesses seeking succession planning and revitalization services, while its EC business sells electrical products to retail and wholesale customers. Revenue streams include fees from clinical and safety testing, production of genetically modified animals, sales of model mice, and development of biomarkers under the CRO segment. The Diagnostic Analysis segment earns from pathology services, gene analysis, and drug discovery support. The TGBS segment generates income through advisory services and EC sales of electrical products. TransGenic Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TransGenic Group stock

Payables Turnover Ratio of TransGenic Group is 25.84 in 2026.

Payables Turnover Ratio of TransGenic Group changed from 26.21 to 25.84, representing a -1.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Payables Turnover Ratio TransGenic Group since 2006 – with annual values, charts, and detailed analysis.

Payables turnover measures how quickly a company pays its suppliers. Lower turnover may indicate better payment terms or cash flow management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Payables Turnover Ratio's TransGenic Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Payables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Payables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — TransGenic Group

All Key Metrics — TransGenic Group